Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 558

Dr Jonathan Ledermann - University College Hospital, London, UK

Dr Jonathan Ledermann speaks to ecancer at ESMO 2019 in Barcelona about the ARIEL3 trial.

The analysis that Dr Ledermann describes is an update from ESMO 2017. They wanted to see whether rucaparib was similar or improved a partial or complete response to platinum based chemotherapy.

He highlights that it is not just a maintenance drug, but it also has a therapeutic effect.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation